Deficient IL-2 Produced by Activated CD56+ T Cells Contributes to Impaired NK Cell-Mediated ADCC Function in Chronic HIV-1 Infection

Zhe Xie†, Jiajia Zheng‡, Yuya Wang†, Dan Li‡, Tuohutaerbieke Maermaer†, Yuantao Li†, Jing Tu†, Qiang Xu†, Hua Liang‡*, Weiping Cai‡* and Tao Shen†*

† Department of Microbiology and Infectious Disease Center School of Basic Medical Sciences, Peking University, Beijing, China, ‡ Department of Laboratory Medicine, Peking University Third Hospital, Beijing, China, † State Key Laboratory of Infectious Disease Prevention and Control, National Center for AIDS/STD Control and Prevention, China CDC, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Beijing, China, * Department of Infectious Diseases, Guangzhou Eighth People’s Hospital, Guangzhou Medical University, Guangzhou, China

Background: Antibody-dependent cellular cytotoxicity (ADCC), which mainly mediated by natural killer (NK) cells, may play a critical role in human immunodeficiency virus type-1 (HIV-1) disease progression. However, the potential mechanisms that affecting NK-mediated ADCC response are still not well-elucidated.

Methods: Antigen-antibody complex model of Ab-opsonized P815 cells was adopted to induce a typical non-specific ADCC response. The capacities of HIV-1 specific NK-ADCC were measured by using the combination model of gp120 protein and plasma of HIV-1 elite controllers. The levels of plasma cytokine were measured by ELISA. Anti-IL-2 blocking antibody was used to analyze the impact of activated CD56+ T cells on NK-ADCC response.

Results: IL-2, IL-15, IFN-α, and IFN-β could effectively enhance the non-specific and HIV-1-specific NK-ADCC responses. Compared with healthy controls, HIV-1-infected patients showed decreased plasma IL-2 levels, while no differences of plasma IFN-α, IL-15, and IFN-β were presented. IL-2 production was detected from CD56+ T cells activated through antibody-dependent manner. The capability of NK-ADCC could be weakened by blocking IL-2 secretion from activated CD56+ T cells. Although no difference of frequencies of CD56+ T cells was found between HIV-1-infected patients and healthy controls, deficient IL-2 secretion from activated CD56+ T were found in chronic HIV-1 infection.

Conclusions: The impaired ability of activated CD56+ T cells to secreting IL-2 might contribute to the attenuated NK cell-mediated ADCC function in HIV-1 infection.

Keywords: NK cells, CD56+ T cells, ADCC, HIV-1, IL-2
INTRODUCTION

The induction of a broad range of neutralizing antibodies and cytotoxic T lymphocyte (CTL) responses may contribute to the development of anti-HIV strategies (1), but studies have shown that non-neutralizing HIV-specific antibodies are also play an important role in preventing or controlling HIV infection. These antibodies can bind to infected cells and recruit innate immune effector cells, such as NK (natural killer) cells to clear the infected cells through antibody-dependent cellular cytotoxicity (ADCC). NK cells express CD16 (FcγRIIIa) that binds the constant (Fc) domain of IgG antibodies. CD16 engagement is a strong activator of NK cell function, and allows antigen-specific recruitment of NK responses. Over the past decades, numerous studies have confirmed that NK-ADCC modulated by cytokines in HIV-1 infection are important roles in anti-tumor immunotherapy or other diseases (9–11). In fact, the profiles of plasma/serum cytokines during HIV infection are complex and diverse. Studies have shown that high levels of soluble IL-10 (12), IL-7 (13), GM-CSF (14), and TNFα (15) have been observed in the plasma of HIV-1-infected patients. In addition, other studies have shown that the production of IL-12 and IL-15 were decreased in HIV-infected individuals (16, 17). However, activities of NK-mediated ADCC modulated by cytokines in HIV-1 infection are poorly understood.

In this study, we systemically evaluated the effects of different cytokines on NK cell-mediated ADCC response and screened out the cytokines that could enhance NK-ADCC response. We also evaluated serum cytokines profiles in HIV-1-infected patients and explored the potential mechanisms weakening NK-ADCC function in chronic HIV infection. Exploring how to enhance the host ADCC function will provide support for the realization of new HIV-related immune prevention and control strategies.

MATERIALS AND METHODS

Study of Population

In our study, 50 HIV-positive patients were recruited from Guangdong No.8 People’s Hospital. 30 healthy adults who had negative HIV-1 infection were recruited as healthy controls. Blood routine test, clinical biochemistries, CD4+/CD8+ T cells count, HIV antibody, HCV antibody, HIV RNA and HCV RNA were detected for all participants (Supplementary Table 1). All subjects have no HBV and HCV infection. Whole venous blood samples were collected from each individual. Peripheral blood mononuclear cells (PBMCs) were prepared from fresh EDTA anti-coagulated peripheral blood using Histopaque-1077 (Sigma-Aldrich, USA, 10771-500 ml) and were stored (5 × 10⁶ cells per vial) in liquid nitrogen till use. Serum and EDTA anti-coagulated plasma were stored at −80°C until use. This study was approved by the ethics committee of Peking University and informed consents were obtained from all cases.

Pre-incubation With Cytokines of PBMCs

25 types of recombinant human cytokines (IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12, IL-13, IL-15, IL-17A, IL-17F, IL-21, IL-22, IL-23, SCF, M-CSF, GM-CSF, G-CSF, TNF-α, IFN-α, IFN-β, IFN-γ, and IFN-λ) were purchased from PeproTech, Inc. (USA). All the lyophilized powder was reconstituted in double distilled water, sodium phosphate, acetic acid or phosphate buffer solution according to the protocol described and then diluted with PBS comprising 5% of trehalose and sub-packaged as 10 μl per tube for further use. All the dilution buffers were purchased from Multi sciences, China.

PBMCs from healthy donors were thawed and then rested overnight at 37°C. Samples were seeded as 1 × 10⁵ cell/100 μl/well in 96 well-plates. Twenty-five types of cytokines were reconstituted as 10 mg/ml and 1 μl was added into a 200 μl medium per well to construct a 50 ng/ml concentration. PBS comprising 5% of trehalose was used as negative control. Samples were incubated in a humidified CO₂ incubator at 37°C for 12 h for further analysis.

NK Cell-Mediated Nonspecific ADCC Activity With Stimulation of Ab-Opsonized P815 Cells

PBMCs or purified NK cells were stimulated with P815 mouse mastocytoma cells plus P815-specific Abs (1:100 dilution of polyclonal rabbit anti-mouse lymphocyte serum, Accurate Chemical & Scientific Corp., Westbury, NY) and ADCC responses were indicated through CD107a production and IFN-γ secretion from activated NK cells. P815 cells were used as target cells (18). PBMCs or purified NK cells were stimulated with P815 cells alone or Ab-opsonized P815 cells at an E:T ratio of 10:1. Then the Brefeldin-A (10 μg/ml, Sigma, St. Louis, MO, USA), GolgiStop (5 μg/ml, BD Biosciences) and anti-CD107a PE-Cy5 (clone H4A3, BD Biosciences) were added to cell medium after 1 h incubation and continued to incubate for up to 6 h in a humidified CO₂ incubator at 37°C. Cells were stained with anti-CD3 eFluor 450 (clone UCHT1) and anti-CD56 PE-Cy7 (clone B159) and fixed by 2% PFA. All data were acquired on BD FACS Fortessa (BD Biosciences, San Jose, CA, USA) and analyzed by FlowJo software (Treestar, Ashland, OR, USA).
Activation of NK Cells Mediated by CD16 Cross-Linking

PBMCs or purified NK cells were stimulated with 10 µg/ml of anti-CD16 antibody (clone 3G8, Santz Cruz biotechnology, Santa Cruz, CA, USA) or mouse IgG1(κ) (clone X40, BD Biosciences) isotype control for 30 min on ice. Cells were washed to remove unbound antibody and incubated with 10 µg/ml of goat anti-mouse IgG1 F(ab')2 (Santz Cruz biotechnology, Santa Cruz, USA). The Brefeldin-A (10 µg/ml, Sigma, St. Louis, MO, USA), GolgiStop (5 µg/ml, BD Biosciences) and anti-CD107a PE-Cy5 (clone H4A3, BD Biosciences) were added to cell medium after 1 h incubation and continued to incubate for up to 5 h in a humidified CO2 incubator at 37°C. Then, cells were washed and stained with anti-CD3 eFluor 450 (clone UCHT1) and anti-CD56 PE-Cy7 (clone B159) and fixed by 2% paraformaldehyde (PFA). All data were acquired on BD FACS Fortessa (BD Biosciences, San Jose, CA, USA) and analyzed by FlowJo software (Treestar, Ashland, OR, USA).

NK Cell-Mediated Cytotoxicity Detected by Rapid Fluorometric Assay

A rapid fluorometric ADCC assay was performed as described previously (19). 1 × 10⁶ target cells were double-stained by 5 µm CFSE (Molecular Probes, Eugene, OR, USA) and 5 µm PKH-26 (Sigma, St. Louis, MO, USA). PBMCs pre-incubated with cytokines were used as the effector cells and incubated with P815 alone or Ab-opsonized P815 cells complex at an E:T ratio of 1:1. After 6 h incubation, cells were washed and fixed in cold 2% paraformaldehyde. Samples were run on BD FACS Fortessa (BD Biosciences, San Jose, CA, USA) and the abilities of NK cells killing target cells influenced by cytokines were analyzed by FlowJo software (Treestar, Ashland, OR, USA).

Image Analysis of CD16/CD69/CD161 Expressions on NK Cells

To compare the surface expression of CD16, CD69, and CD161 on NK cells at the whole range and single-cell level, PBMCs of healthy donors were pre-incubated with cytokines for 12 h and then washed with PBS. All samples were stained with anti-CD3 eFluor 450 (ebioscience, clone UCHT1), anti-CD16 APC-Cy7 (BD, clone 3G8), anti-CD56 PE-Cy7 (BD, clone B159), anti-CD69 APC (BD, clone FN50), and anti-CD161 PE-Cy5 (BD, clone DX12). All antibodies were purchased from BD Biosciences (San Diego, CA, USA) except anti-CD3 from eBioscience (San Diego, CA, USA). NK cells were defined as phenotype of CD3−/CD16+/CD69−/CD161− and the frequencies of CD16, CD69 and CD161 expresions on NK cells were analyzed. CD16/CD69/CD161 expressions on NK cells were acquired on BD FACS Fortessa (BD Biosciences, USA) and then analyzed by FlowJo software (Treestar, Ashland, OR, USA).

The prepared samples were also run on ImageStream χ MarkII system (Amnis Corporation, Seattle, WA, USA) to acquire the data of CD16/CD69/CD161 expressions on single-cell. Twenty thousand events were collected for each sample and single-color control was used to create a compensation matrix to correct for spectral overlap. Collected data were analyzed using IDEAS 3.0 software (Amnis Corporation, Seattle, WA, USA).

HIV-1-Specific ADCC Activity Assay

HIV-1CSN54 gp120 peptides (1.0 mg/ml), purified HIV-1CSN54 gp120 protein (1.0 mg/ml), and plasma of HIV-1 elite controllers were kindly presented by China National Center for AIDS/STD Control and Prevention. Gp120 mixed overlapping peptides or purified HIV-1CSN54 gp120 protein were dissolved to a concentration of 1 µg/ml in PBS and were added into 96 well flat-bottom plates (Corning Costar, USA) at 4°C overnight. After washing for 3 times with 0.05% Tween 20 in PBS (PBS-T), the plates were blocked with blocking buffer (5% skim milk and 2% bovine albumin in PBS) for 1 h at room temperature (RT). Plates were then washed five times with PBS-T. 100 µl plasma of HIV-1 elite controller diluted by PBS (1:1,000) were added into each of the 96 wells and incubated at room temperature for 2 h. After washing, plates were incubated with PBMC from HIV-1-infected patients and the HIV-1-specific ADCC activity was assayed as mentioned above.

ELISA Assay

The levels of secreted IL-2, IL-15, IFN-α, and IFN-β in serum or culture supernatants were detected by ELISA kits IL-2 (eBioscience, San Diego, CA, USA, sensitivity 2 pg/ml), IL-15 (eBioscience, sensitivity 20 pg/ml), IFN-α (Invitrogen, San Diego, CA, USA, sensitivity 3.2 pg/ml), and IFN-β (PBL assay science and assay range 50–4,000 pg/ml), according to the manufacturer's instruction.

RNA Extraction and IL-2 mRNA Expression Analysis

Total RNA was extracted from cells by using Trizol reagent (Invitrogen, USA) according to the manufacturer's protocol. And cDNA was reverse transcribed from 3.0 µg of total RNA with random hexamer primers using a Maxima® First Strand cDNA Synthesis Kit (Fermentas, USA). qRT-PCR was performed on the LightCycler® 480Ii-real-time PCR system (Roche, USA) using the QuantiTect SYBR Green PCR kit (Roche, USA). The 20 µl reaction mix contained 200 nM of each primer, 100 µl of LightCycler 480 SYBR green I master mix (Roche), and 1 µl of template cDNA. The primers for the IL-2 gene were F (5′- CAG GAT GGA GAA TTA CAG GAA CCT-3′) and R (5′- TTG GCA GAA GCT GCA AAT CTG GCC GTC-3′), and those used for β-actin gene were F (5′- TTG GCA GAA GCT GCA AAT CTG GCC GTC-3′) and R (5′- ATG GTA CAA TTC CCT CCA CTC GCT-3′). For gene IL-2 and β-actin, the amplifications consisted of 10 min at 95°C followed by 40 cycles, each consisting of denaturing for 15 s at 95°C, annealing for 1 min at 60°C, and elongation for 30 s at 60°C. All PCR were performed in triplicate using cDNA synthesized from the same batch and starting amount of total RNA. The expression of IL-2 gene was determined using the comparative Ct method (2-ΔCt) after normalization to β-actin.

Sorting of NK Cells

NK cells were sorted from PBMCs by EasySep Human NK cell Enrichment Kit according to the manufacturer’s instruction. In brief, NK cells were negatively isolated by targeting non-NK cells (i.e., T cells, B cells, stem cells, dendritic cells, monocytes, granulocytes and erythroid cells) for removal with antibodies...
FIGURE 1 | IL-2, IL-15, IFN-β, and IFN-α could augment the nonspecific NK-ADCC function. (A) Representative flow plots of degranulation of NK cells in response to Ab-opsonized P815 cells (P815 + Ab), or medium or P815 cells alone after pre-incubation with different cytokines (50 ng/ml) for 12 h. (B) IL-2, IL-15, IFN-β, and IFN-α (Continued)
recognizing specific cell surface markers. Unwanted cells were bound with antibodies and magnetic particles, and separated without columns using an EasySep magnet. Desired cells are simply poured off into a new tube. The purity of NK cells obtained in this fashion was consistently >90%.

**Sorting of CD56⁺ T Depleted Lymphocytes by BD FACS AriaIII**

PBMCs were stained with anti-CD3 PE (ebioscience, clone UCHT1), anti-CD56 PE-Cy7 (BD, clone B159) for 30 min at room temperature. CD56⁺ T cells were depleted by gathering CD3⁺ CD56⁻ and CD3⁻ cells on BD FACS Aria III (BD Biosciences, San Jose, CA). Only sorted samples with CD56⁺ T cells less than 5% were used in subsequent experiments.

**Evaluation of IL-2 Secretions From CD56⁺ T Cells During the Process of ADCC**

The IL-2 secretions of CD56⁺ T cells, NK cells and T cells were determined by Ab-opsonized P815 cells, IL-2, IL-15, IFN-α and IFN-γ cytokines plus HIV-1 gp120 protein plus HIV-1 elite controller plasma models. PBMCs were stained with anti-CD3 eFluor 450 (clone UCHT1), anti-CD56 PE-Cy7 (clone B159), anti-CD107a PE-Cy5 (clone H4A3) and anti-IL-2 FITC (clone MQ1-17H12), and fixed by 2% PFA. All data were acquired on BD FACS Fortessa (BD Biosciences, San Jose, CA, USA) and analyzed by FlowJo software (Treestar, Ashland, OR, USA).

**Blocking of IL-2 Function**

IL-2 monoclonal functional antibody (AB12-3G4, eBioscience, USA) were added as 100 ng/ml/well in NK cell-mediated ADCC activity in Ab-opsonized P815 cells model and CD16 cross linking model to block IL-2 function.

**Transwell Culture Assay**

Purified NK cells and CD56⁺ T cells from healthy controls (n = 10) were cultured in complete RPMI1640 medium containing 10% of fetal bovine serum (R10 medium) (Gibco BRL, Grand Island, NY, USA) and 1% of penicillin and streptomycin (Gibco) to the final volume of 1 × 10⁶/ml and 1 × 10⁵ cells and were seeded in the bottom wells of 96-well transwell plate (Corning Lifescience, Lowell, MA, USA). A total of four groups were set: a) NK cells alone; b) NK cells + IL-2 antibody; c) NK cells + CD56⁺ T cells (transwell); d) NK cells + CD56⁺ T cells (transwell) + IL-2 antibody. The final concentrations of NK cells, CD56⁺ T and IL-2 antibody were 1 × 10⁵/well, 1 × 10⁵/well and 100 ng/ml, respectively. Ab-opsonized P815 (1 × 10⁵/well) cells were added to all of the wells (top and bottom). After incubation for 6 h, NK cells were collected to degrade granulation with BD FACS Fortessa (BD Biosciences, San Jose, CA, USA) and then data was analyzed by FlowJo software (Treestar, Ashland, OR, USA).

**Statistical Analysis**

All the statistical and graphic analyses were performed using GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA) or Microsoft Excel 2007. Data were expressed as mean ± SD. Comparisons between groups were performed using Mann-Whitney U-test, non-parametric t-test, or Wilcoxon matched-pairs signed rank test when necessary. All P-values were two-tailed and considered significant when lower than 0.05.

**RESULTS**

**Screening and Identification of Cytokines Enhancing the Non-specific NK-Mediated ADCC Responses**

It has been reported that cytokines play an important role in regulation of NK cell activation and natural cytotoxicity (20, 21). In this study, firstly, healthy PBMCs were pre-incubated with 25 recombinant human cytokines, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12 p70, IL-13, IL-15, IL-17A, IL-17F, IL-21, IL-22, IL-23, SCF, M-CSF, GM-CSF, G-CSF, TNF-α, IFN-α, IFN-β, IFN-γ, and IFN-λ, respectively. Among these 25 cytokines, IL-2, IL-15, IFN-α, and IFN-β could significantly enhance CD107a expressions in NK cells with the stimulation of Ab-opsonized P815 cells (P < 0.001, Figures 1A,B). Similarly, IFN-γ secretion from NK cells were also significantly increased with the stimulation of Ab-opsonized P815 cells in the presence of IL-2 (P < 0.0001), IL-15 (P < 0.0001), IFN-α (P = 0.002), and IFN-β (P < 0.001) (Figures 1C,D). Moreover, we observed the CD107a production and IFN-γ secretion were increased as the pre-incubation time for these cytokines was extended or the concentrations of cytokines were increased (Figures 1E,F). These data suggested that the selected cytokines exerted stable and sustained effect on priming of NK cell-mediated ADCC response.

Next, to address antibody-dependent lytic capacity of NK cells, target P815 cells were pre-stained with PKH26 and CFSE, and a rapid fluorometric ADCC (RFADCC) assay was employed...
to detect the frequencies of CFSE<sup>-/LOW</sup> target cells. When P815 cells were lysed by NK cells, the double stained P815 cells (PKH26<sup>+</sup>CFSE<sup>-</sup>) were changed as PKH26<sup>+</sup>CFSE<sup>-</sup> (Figure 1G). Our data showed that the percentages of P815 target cells killed by NK cells were significantly elevated when pre-stimulated with IL-2 (<i>P</i> = 0.009), IL-15 (<i>P</i> < 0.001), IFN-α (<i>P</i> = 0.003), and IFN-β (<i>P</i> = 0.008). Remarkably, our results suggested that IL-2, IL-15, IFN-α, IFN-β could potentiate NK cells-mediated cytotoxicity (Figure 1H).

In addition, NK cells could also be triggered by IL-2 (<i>P</i> = 0.003), IL-15 (<i>P</i> < 0.001), IFN-α (<i>P</i> < 0.001), and IFN-β (<i>P</i> = 0.002) to achieve degranulation after CD16 cross-linking with anti-CD16 monoclonal Ab (Supplementary Figure 1).

Taken together, these results confirmed that cytokines IL-2, IL-15, IFN-α, IFN-β could enhance the non-specific NK-ADCC responses.

**IL-2, IL-15, IFN-α, IFN-β Promoted CD69 Expressions on the Surface of NK Cells**

In order to explore the potential mechanisms involved in the enhancement of NK-ADCC response induced by the candidate cytokines, we detected the expressions of CD16, CD161, and CD69, which represented the activation of NK cells in the presence or absence of specified cytokines. As indicated in Figure 2A, CD69<sup>+</sup> NK cells were significantly elevated after stimulation with IL-2 (<i>P</i> = 0.013), IL-15 (<i>P</i> < 0.001), IFN-α (<i>P</i> < 0.001), and IFN-β (<i>P</i> < 0.001). However, there were no significant differences in CD16 and CD161 expressions before and after cytokines stimulations. The expressions of CD16, CD161, and CD69 on CD56<sup>dim</sup> NK cells were confirmed at single-cell level by image analysis (Figure 2B). CD69 showed a significantly enhanced expression upon the stimulation with cytokines (Figure 2B). CD69 is a classical marker of lymphocyte activation due to its rapid appearance on the surface of the plasma membrane after stimulation (22). Overall, IL-2, IL-15, IFN-α, and IFN-β enhanced ADCC responses through promoting the activated status of NK cells.

**CD56<sup>+</sup> T Cells Could Secrete IL-2 via Antibody-Dependent Immune Response**

In order to explore the potential mechanisms that might affect NK-ADCC activity, we compared the cellular degranulation and IFN-γ secretion between purified NK cells and NK cells in bulk PBMCs. Our results revealed lower expressions of CD107a (<i>P</i> = 0.015) and IFN-γ (<i>P</i> = 0.004) in purified NK cells compared with NK cells in PBMCs after co-cultured with Ab-opsonized P815 cells (Figures 5A,B), suggesting that other cells in PMBCs may play an auxiliary role in NK-ADCC process.

Considering that IL-2 could augment NK-mediated ADCC responses in vitro and that lower levels of plasma IL-2 were presented in HIV-1-infected patients, we examined whether IL-2 production existed in bulk PBMC during NK-ADCC response. As speculated, with the stimulation of Ab-opsonized P815 cells, IL-2 production was significantly elevated both in protein level (<i>P</i> = 0.001) as detected in supernatants and in mRNA level (<i>P</i> = 0.008) as detected in cell pellets (Figure 5C). Our previous results demonstrated that peripheral blood CD56<sup>+</sup> T cells were capable to mediate antibody-dependent response (19). Four outlier individuals in P815+Ab group in Figure 5C were found to have relatively higher frequencies of CD56<sup>+</sup> T cells but not CD16 expression on CD56<sup>+</sup> T cells and frequencies of NK cell and its subsets, compared with that of other individuals (data not shown). Furthermore, we found that CD56<sup>+</sup> T cells could also produce IL-2 via antibody-dependent activation during NK-ADCC progress. As shown in Figures 5D,E, and Supplementary Figure 2, CD56<sup>+</sup> T cells in PBMCs produced much higher levels of IL-2 than conventional T cells (CD56<sup>−</sup>T) (<i>P</i> = 0.015) and NK cells (<i>P</i> = 0.014) with the stimulation of Ab-opsonized P815 cells. In contrast, CD56<sup>−</sup> T cells produced higher levels of IL-2 than NK cells (<i>P</i> < 0.001) and CD56<sup>+</sup> T cells (<i>P</i> < 0.001) with the stimulation of PMA plus Ionomycin (PI). More importantly, similar results were observed in the HIV-1-specific ADCC and CD16 cross-linking system, that CD56<sup>+</sup> T cells also produced much higher levels of IL-2 than CD56<sup>−</sup> T cells (HIV; <i>P</i> = 0.03, CD16 cross linking; <i>P</i> < 0.001) and NK cells (HIV; <i>P</i> = 0.009, CD16 cross linking; <i>P</i> < 0.001) (Figures 5E,G and Supplementary Figures 3A,B). These results indicated that CD56<sup>+</sup> T cells can produce IL-2 during NK-ADCC responses. These results indicated that CD56<sup>+</sup> T cells can produce IL-2 during NK-ADCC responses.
Dysfunction of CD56+ T Cells Contributes to the Impaired NK-ADCC in Chronic HIV-1 Infection

To further confirm that IL-2 secreted by CD56+ T cells during NK-ADCC response contributes to ADCC effect of NK cells, we sorted lymphocytes and CD56+ T depleted lymphocytes by BD FACS Aria III from PBMC and NK-mediated ADCC were then detected in the stimulations of Ab-opsonized P815 cells (Figure 6A). As shown in Figure 6B, lower CD107a production ($P = 0.020$) and weaker IFN-γ secretion ($P = 0.031$) were found in NK cells from CD56+ T depleted lymphocytes than from intact lymphocytes (Figure 6B). Furthermore, IL-2 functional
blocking antibody was added to block the production of IL-2 during ADCC effect. The cellular degranulation of NK cells was weakened after IL-2 blockade either in the stimulations of Ab-opsonized P815 cells ($P = 0.004$) (Figure 6C) or CD16 cross-linking model ($P = 0.004$) (Supplementary Figure 4), indicating that IL-2 was involved in the process of NK-ADCC response. Furthermore, transwell experiment indicated that NK cells showed a stronger degranulation ability ($P = 0.002$) when purified CD56$^+$ T cells were placed in the transwell insert, while the ability was decreased after IL-2 functional antibodies were added ($P = 0.004$) (Figure 6D). Taken together, our results demonstrated that IL-2 derived from activated CD56$^+$ T cells could facilitate NK cell-mediated ADCC responses.

In order to figure out whether CD56$^+$ T cells were involved into the impaired NK-ADCC function in HIV-1 infection, we compared the frequencies of CD56$^+$ T cells between HIV-1-infected patients and healthy controls and no significant difference was found (Figure 6E). However, a significantly higher IL-2 secretion by CD56$^+$ T cells from healthy controls than from HIV-1-infected patients ($P < 0.001$) was observed upon stimulation with Ab-opsonized P815 cells (Figure 6F). The impaired abilities of CD56$^+$ T cells to secret IL-2 may contribute to weaken NK cell-mediated ADCC function in HIV-1 infection.

**DISCUSSION**

NK cells play a key role in immune response against HIV infection. Increased NK cell activity, reflecting by higher cytotoxic capacity, IFN-γ and chemokines production, has been associated with resistance to HIV infection and delayed AIDS progression, indicating the significance of NK cells in antiviral response. So far, there are few systematic studies about screening and identification of cytokines which can enhance NK-mediated ADCC response. In this study, we found IL-2, IL-15, IFN-α, and IFN-β could significantly augment NK cell-mediated non-specific and HIV-1 specific ADCC responses. As a T-cell growth factor, IL-2 is predominantly secreted by CD4$^+$ T cells.
FIGURE 5 | IL-2 produced by CD56+ T cells facilitates NK-ADCC response. (A) Representative flow plots of IFN-γ secretion and CD107a expression of purified NK cells and of NK cells from bulk PBMCs with the stimulation of Ab-opsonized P815 cells. (B) IFN-γ secretion and CD107a expression of purified NK cells were lower than that of NK cells from bulk PBMCs (n = 10) during ADCC response. (C) Secretion of IL-2 during ADCC response. PBMCs were stimulated by P815, Ab-opsonized P815 cells or PI (PMA + ionomycin) for 12 h at 37°C. Culture supernatants were collected and IL-2 level was detected by ELISA. Cell pellets were also collected and IL-2 mRNA level in PBMCs was detected by qRT-PCR (n = 10). (D) Representative flow plots of IL-2 and CD107a expressions on CD56− T cells, CD56+ T cells and NK cells with the stimulation of P815 cells only, Ab-opsonized P815 cells or PI. (E) Comparison of the abilities of IL-2 secretion and CD107a expression among CD56− T cells, CD56+ T cells and NK cells with different stimulators (n = 10). (F) Representative flow plots of IL-2 and CD107a expressions on CD56− T cells, CD56+ T cells and NK cells with the HIV-1 elite plasma in the presence or absence of gp120 protein antigen. (G) Comparison of the abilities of IL-2 secretion and CD107a expression among CD56− T cells, CD56+ T cells and NK cells with different stimulators (n = 5). All P-values are two-tailed and significantly different when the value is <0.05.

to regulate the differentiation and proliferation of lymphocytes. IL-2 production declines and IL-2-producing T cells is impaired in chronically HIV-1-infected patients, as indicated by loss of CD4+ T cells and progression to AIDS (24). The decreased plasma IL-2 levels were also observed in our HIV-1-infected patients compared with healthy controls. Numerous studies have
shown that ART and in vivo administration of IL-2 could partially restore NK cell distribution and function in HIV-1 infection (25, 26). Moreover, in our study, we found that CD56+ T cells could produce much higher levels of IL-2 compared with conventional T cells during NK-ADCC process in the stimulations of Ab-opsonized P815 cells or by CD16-cross linking as shown in the Figure 5D and Supplementary Figures 1, 2. As expected, conventional T cells could produce much higher levels of IL-2 than CD56+ T cells in the stimulation of PMA plus Ionomycin (Figure 5D). In despite of the absolute numbers of conventional CD3+ T cells and its role in IL-2 production, conventional T cells could not secrete enough IL-2 in a Fc-receptor dependent manner. Taken together, we demonstrated that activated CD56+ T cells could produce IL-2 through the antibody-Fc-dependent manner and thus facilitate NK-ADCC response during HIV infection.

Besides, several studies have demonstrated that IL-15 and IFN-α could enhance NK cell-mediated cytotoxicity in HIV-1-infected subjects through increasing chemokines production, inhibiting viral entry to CD4+ T cells and limiting its spread (27, 28). However, we failed to observe any differences of peripheral levels of IL-15 and IFN-α between HIV-1-infected patients and healthy controls in our study. Actually, there are also other cytokines which were not mentioned in our study but still could augment NK cells functions. A study have reported that IL-18 could augment IFN-γ production and ADCC function of NK cells activated through Fc receptors in vitro, and could synergy with IL-2, IL-15, and IL-21 to potentiates NK cell effector function.
Xie et al. Deficient IL-2 Weaken ADCC Function

FIGURE 7 | Schematic diagram of interaction between NK cells and CD56+ T cells during the process of HIV-1-specific ADCC immune response.

function during innate and adaptive immune responses (29). IL-27 acts as a pro-inflammatory cytokine that, in concert with other DC-derived cytokines, hierarchically contributes to NK cells activation and effector functions (30). It is unfortunately that IL-18 and IL-27 were not included in our present study. We will further investigate the synergistic effect of IL-18/IL-27 and other cytokines such as IL2/IL15/IFNα/IFNβ on NK cells ADCC functions in our following research.

Many studies reported the levels of cytokines in healthy individuals and HIV or HBV or HCV infected patients (31, 32). However, the ranges of many cytokines did not show much consistency across different recruited cohorts. In addition, to some extent, different detecting reagent kits may influence its consistency. Usually, the intense early cytokine storm occurs in acute HIV-1 infection. While, the decreased percentage of cells expressing IL-2 and serum IL-2 level were found in chronic and progressive HIV infection (33–35), which is consistent with our data. In our study, there are great differences in cytokine levels among different healthy individuals. The levels of most of these four cytokines (IL-2, IL-15, IFN-α, and IFN-β) are very low, even below the detection limit, while higher values were only found in very few individuals.

In addition, our experiments demonstrated that the ability of purified NK cells to mediate ADCC effects were significantly weakened compared to NK cells from bulk PBMCs, suggesting that other cells in PBMCs may facilitate NK-mediated ADCC. A number of studies have demonstrated that cell-to-cell interactions are important for the immune responses of NK cells against viral infections and malignancies (36–38). CD56+ T cells, also termed as CD3+CD56+ NKT-like cells (39, 40), account for 5% to 15% of peripheral blood T-cell pool and are considered as a superior latent source of IFN-γ (19, 41). Most CD3+CD56+ T cells express TCR γδ chain (42). Recent study from our lab also confirmed that CD56+ T cells can mediate antibody-dependent responses through CD16, and the impaired immune activities mediated by CD56+ T cells were observed in long-term HIV-1-infected patients (19). On the other hand, the characteristics of CD56+ T cell-mediated antibody-dependent responses were different from ADCC activities mediated by classic NK cells. NK-mediated ADCC was marked by both powerful degranulation and IFN-γ production while degranulation capacity was significantly weaker in CD56+ T cell-mediated antibody-dependent response though a comparable level of IFN-γ production was observed (Figure 7) (19). Currently, in this study, we demonstrated that CD56+ T cells could also secret IL-2 during the process of NK-ADCC and the ability was impaired in HIV infection. The decreased level of plasma IL-2 in HIV-1-infected individuals may be one of the critical reasons for the weakened ADCC activities, indicating that IL-2 produced by activated CD56+ T cells may actually facilitate NK cell-mediated ADCC responses.

CD56+ T is a mixed cell population, composing of many different cell types and might including a partial of mucosal associated invariant T cell (MAIT) and γδ+ T cells. Our previous work analyzed the phenotypic characteristics of CD56+ T cells according to the CD4 and CD8 expressions (19). We demonstrated a decreased frequency of CD4+CD56+ T cells but increased frequency of CD8+CD56+ T cells in HIV-1 infection. However, CD8+CD56+ T subset showed less capacity to mediate ADCC compared with DN (CD4−CD8−) subset. A proportion of human MAIT cells in peripheral blood express CD56, and CD56+ MAIT cells may have a higher capacity to respond to IL-12 and IL-18 (42). However, it has not been reported whether MAIT has ADCC or Fc receptor-dependent activation. Although some of γδ+ T cells were reported to express CD16 and have the ability to mediate ADCC function (43, 44), we still confused...
whether CD56⁺ γδ⁺ T cells express CD16 and have the ability to mediate ADCC function or not. Our subsequent studies will be interested in studying the potential capacity and mechanism of Fc dependent activation of CD56⁺ MAIT cells and γδ⁺ CD56⁺ T cells, and its potential significance in viral infections such as HIV.

In summary, the present study demonstrated that cytokines IL-2, IL-15, IFN-α, IFN-β can enhance the ADCC effect of NK cells in vitro. Also, we provided a novel mechanism that IL-2 secreted by activated CD56⁺ T cells in an antibody-dependent manner can enhance the capabilities of NK cells to mediate ADCC response. Therapeutic strategy of promoting IL-2 secretion by activating CD56⁺ T cells in vivo to enhance NK-mediated ADCC activities may bode well for the HIV immunotherapy in the future.

DATA AVAILABILITY

All datasets generated for this study are included in the manuscript and the Supplementary Files.

ETHICS STATEMENT

This study was carried out in accordance with the recommendations of the ethical committee of our Institution (Peking University, China) with written informed consent from all subjects. All subjects gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the ethics committee of Peking University.

AUTHOR CONTRIBUTIONS

TS, JZ, and HL designed, analyzed and provided overall guidance for the experiments. ZX, YW, TM, DL, JT, QX, and YL performed the experiments. WC provided the clinical HIV-1-infected samples. JZ, ZX, and TS wrote the manuscript. All authors read and approved the final manuscript.

FUNDING

The study was supported by the National Science and Technology Major Project of China (2017ZX10202101-003, 2018ZX10731101-001-005, and 2018ZX09739002-003) and National Natural Science Foundation of China (81873859, 31600734).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2019.01647/full#supplementary-material

REFERENCES

1. Walker BD, Burton DR. Toward an AIDS vaccine. Science. (2008) 320:760–4. doi: 10.1126/science.1152622
2. Hessel AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, et al. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. (2007) 449:101–4. doi: 10.1038/nature06106
3. Ahmad R, Sindhu ST, Toma E, Morisset R, Vincetej J, Menezes J, et al. Evidence for a correlation between antibody-dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol. (2001) 21:227–33. doi: 10.1023/A:1011087132180
4. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, et al. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis. (1999) 180:1338–41. doi: 10.1086/314988
5. Gomez-Roman VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, Flores R, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol. (2005) 174:2185–9. doi: 10.4049/jimmunol.174.4.2185
6. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. (2012) 366:1275–86. doi: 10.1056/NEJMoai1113425
7. Kong D, Wang Y, Ji P, Li W, Ying T, Huang J, et al. A defucosylated bispecific multivalent molecule exhibits broad HIV-1-neutralizing activity and enhanced antibody-dependent cellular cytotoxicity against reactivated HIV-1 latently infected cells. AIDS. (2018) 32:1749–61. doi: 10.1097/QAD.0000000000014869
8. Lee WS, Richard J, Lichtfuss M, Smith AB, 3rd, Park J, Courter JR, et al. Antibody-Dependent Cellular Cytotoxicity against Reactivated HIV-1–Infected Cells. J Virol. (2015) 90:2021–30. doi: 10.1128/JVI.02717-15
9. Ziblat A, Nunez SY, Raffo Iraologaitia XL, Spallanzani RG, Torres NI, Sierra JM, et al. Interleukin (IL)-23 Stimulates IFN-gamma Secretion by CD56(bright) natural killer cells and enhances IL-18-driven dendritic cells activation. Front Immunol. (2018) 8:1959. doi: 10.3389/fimmu.2017.01959
10. Ewen EM, Pahl JHW, Miller M, Watzl C, Cerwenka A. KIR downregulation by IL-12/15/18 unleashes human NK cells from KIR/HLA-I inhibition and enhances killing of tumor cells. Eur J Immunol. (2018) 48:355–65. doi: 10.1002/eji.201747128
11. Zhang M, Wen B, Anton OM, Yao Z, Dubois S, Ju W, et al. IL-15 enhanced antibody-dependent cellular cytotoxicity mediated by NK cells and macrophages. Proc Natl Acad Sci USA. (2018) 115:E10915–24. doi: 10.1073/pnas.1811615115
12. Srikanth P, Castillo BC, Sridharan G, John TJ, Zachariah A, Mathai D, et al. Increase in plasma IL-10 levels and rapid loss of CD4⁺ T cells among HIV-infected individuals in south India. Int J STD AIDS. (2000) 11:49–51. doi: 10.1258/0956462001914904
13. Napolitano LA, Grant RM, Deeks SG, Schmidt D, De Rosa SC, Herzenberg LA, et al. Increased production of IL-7 accompanies HIV-1–mediated T-cell depletion: implications for T-cell homeostasis. Nat Med. (2001) 7:73–9. doi: 10.1038/83381
14. Hober D, Ajana F, Petit MC, Sartiaux C, Boniface M, Caillaux M, et al. Granulocyte-macrophage colony-stimulating factor and tumor necrosis factor alpha in patients with human immunodeficiency virus (HIV) type 1 infection. Microbiol Immunol. (1993) 37:785–92. doi: 10.1111/j.1348-0421.1993.tb01706.x
15. Rautonen J, Rautonen N, Martin NL, Philip R, Wara DW. Serum interleukin-6 concentrations are elevated and associated with elevated tumor necrosis factor-alpha and immunoglobulin G and A concentrations in children with HIV infection. AIDS. (1991) 5:3139–25. doi: 10.1097/00002030-199111000-00006
16. Marshall JD, Chehimi J, Gori G, Kostman JR, Montaner LJ, Trinchieri G. The interleukin-12–mediated pathway of immune events is dysfunctional in human immunodeficiency virus-infected individuals. Blood. (1999) 94:1003–11.
17. d’Ettorre G, Forcina G, Lichtner M, Mengoni F, D’Agostino C, Massetti AP, et al. Interleukin-15 in HIV infection: immunological and virological
interactions in antiretroviral-naive and -treated patients. AIDS. (2002) 16:181–8. doi: 10.1097/00002030-200201250-00006
18. Liu Q, Sun Y, Rihn S, Nolting A, Tsoukas PN, Jost S, et al. Matrix metalloprotease inhibitors restore impaired NK cell-mediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J Virol. (2009) 83:8705–12. doi: 10.1128/JVI.02666-08
19. Fan X, Zhu L, Qian S, Zhang Z, Fu Y, Xu J, et al. Antibody-dependent CD56+ T cell responses are functionally impaired in long-term HIV-1 infection. Retrovirology. (2017) 13:76. doi: 10.1186/s12977-016-0313-6
20. Ziblat A, Domaica CI, Spallanzani RG, Iraolagoitia XL, Rossi LE, Avila DE, et al. IL-2 stimulates human NK cell effector functions and primes NK cells for IL-18 responsiveness. Eur J Immunol. (2015) 45:192–202. doi: 10.1002/eji.201444699
21. Zwirner NW, Ziblat A. Regulation of NK cell activation and effector functions by the IL-12 family of cytokines: the case of IL-27. Front Immunol. (2017) 8:23. doi: 10.3389/fimmu.2017.00025
22. Cibrian D, Sanchez-Madrid F. CD69: from activation marker to metabolic gatekeeper. Eur J Immunol. (2017) 47:946–53. doi: 10.1002/eji.201646837
23. Chen X, Lin M, Qian S, Zhang Z, Fu Y, Xu J, et al. The early antibody-dependent cell-mediated cytotoxicity response is associated with lower viral set point in individuals with primary HIV infection. Front Immunol. (2018) 9:2322. doi: 10.3389/fimmu.2018.02322
24. Freeman ML, Shive CL, Nguyen TP, Younes SA, Panigrahi S, Lederman MM. Cytokines and T-cell homeostasis in HIV infection. J Infect Dis. (2016) 214(Suppl. 2):S51–57. doi: 10.1093/infdis/jiw287
25. Sellier P, Lafuente-Lafuente C, Bergmann JF. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. (2017) 365:270–1; author reply 271. doi: 10.1056/NEJMoa1709159
26. Michaelsson J, Long BR, Loo CP, Lanier LL, Spotts G, Hecht FM, et al. Immune reconstitution of CD56dim NK cells in individuals with primary HIV-1 infection treated with interleukin-2. J Infect Dis. (2008) 197:117–25. doi: 10.1086/524141
27. Kwak AKR, Talana CA, Blankson JN. Interferon alpha enhances NK cell function and the suppressive capacity of human CD8+ T Cells. J Virol. (2019) 93:2035–45. doi: 10.1128/JVI.00541-18
28. Hua S, Vigano S, Tse S, Zhengyu O, Harrington S, Negron J, et al. Pegylated interferon-alpha-induced natural killer cell activation is associated with lower viral load in patients with HIV-1 infection treated with interleukin-2. J Infect Dis. (2012) 206:1418–27. doi: 10.1093/infdis/jir305
29. Nielsen CM, Wolf AS, Goodier MR, Riley EM. Synergy between common gamma chain family cytokines and IL-18 potentiates innate and adaptive pathways of NK cell activation. Front Immunol. (2017) 8:101. doi: 10.3389/fimmu.2016.00101
30. Kumar P, Rajasekaran K, Nazabakhsh A, Gorski J, Thakar MS, Malaranan S. IL-27 promotes NK cell effector functions via Maf-Nrf2 pathway during influenza infection. Sci Rep. (2019) 9:4984. doi: 10.1038/s41598-019-41478-6
31. Jost S, Quillay H, Reardon J, Peterson E, Simmons RP, Parry BA, et al. Changes in cytokine levels and NK cell activation associated with influenza. PLoS ONE. (2011) 6:e25060. doi: 10.1371/journal.pone.0025060
32. Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, et al. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. (2009) 83:3719–33. doi: 10.1128/JVI.01844-08
33. Klein SA, Dobmeyer JM, Dobmeyer TS, Pape M, Ottmann OG, Helm EB, et al. Demonstration of the Th1 to Th2 cytokine shift during the course of HIV-1 infection using cyttoplasmic cytokine detection on single cell level by flow cytometry. AIDS. (1997) 11:1111–8. doi: 10.1097/00002030-199709300-00005
34. Valdez H, Lederman MM. Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev. (1997) 187–22.
35. Emilie D, Galanaud P. Cytokines and chemokines in HIV infection: implications for therapy. Int Rev Immunol. (1998) 16:705–26. doi: 10.3109/08830189809043015
36. Borg C, Jalil A, Laderach D, Maruyama K, Nakasuhi H, Charrier S, et al. NK cell activation by dendritic cells (DCs) requires the formation of a synapse leading to IL-12 polarization in DCs. Blood. (2004) 104:3267–75. doi: 10.1182/blood-2004-01-0380
37. Gerosa F, Baldani-Guerra B, Nissi C, Marchesini V, Carra G, Trinchieri G. Reciprocating activating interaction between natural killer cells and dendritic cells. J Exp Med. (2002) 195:327–33. doi: 10.1085/jem.2001938
38. Ferlazzo G, Morandi B, D’Agostino A, Meazza R, Melioli G, Moretta A, et al. The interaction between NK cells and dendritic cells in bacterial infections results in rapid induction of NK cell activation and in the lysis of uninfected dendritic cells. Eur J Immunol. (2003) 33:306–13. doi: 10.1002/eji.200310004
39. Jiang Y, Cui X, Cui J, Zhang J, Zhou F, Zhang Z, et al. The function of CD3+ CD56+ NKT-like cells in HIV-infected individuals. Biomed Res Int. (2014) 2014:636265. doi: 10.1155/2014/636265
40. Almendri M, Flanagan BE, Khan N, Alomar S, Christmas SE. Increased numbers and functional activity of CD56+ T cells in healthy cytomegalovirus positive subjects. Immunology. (2014) 142:258–268. doi: 10.1111/immm.112250
41. Guo C, Shen X, Fu B, Liu Y, Chen Y, Ni F, et al. CD3brightCD56+ T cells associate with pegylated interferon-alpha treatment nonresponse in chronic hepatitis B patients. Sci Rep. (2016) 6:25567. doi: 10.1038/rep.2016.227
42. Van Acker HH, Capsomidis A, Smits EL, Van Tendeloo VF. CD56+ γδ T cells mediate antibody-dependent anti-cytomegalovirus activity in HIV-infected individuals. AIDS. (2012) 26:1418–27. doi: 10.3109/08830189809043015
43. Chen Z, Freedman MS. CD16+ gammadelta T cells mediate antibody-dependent cellular cytotoxicity: potential mechanism in the pathogenesis of multiple sclerosis. Clin Immunol. (2008) 128:219–27. doi: 10.1016/j.clim.2008.03.513
44. Couzi L, Pitard V, Sicard X, Garrigue I, Hawchar O, Merville P, Moreau JF, Déchanet-Merville J. Antibody-dependent anti-cytomegalovirus activity of human γδ T cells expressing CD16 (FcyRIIIa). Blood. (2012)119:1418–27. doi: 10.1182/blood-2011-06-363655

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.